Evaxion to announce business update and full year 2024 financial results on april 1, 2025

Copenhagen, denmark, march 27, 2025 - evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on tuesday april 1, 2025, before opening of the nasdaq cm.

EVAX Ratings Summary

EVAX Quant Ranking